Significant Improvement of Persistent Hailey-Hailey Disease with Dupilumab: A Case Report
Main Article Content
Keywords
Hailey-Hailey Diseas, Dupilumab, inflammatory
Abstract
Hailey-Hailey disease is a rare, genetic blistering disease characterized by erythematous, scaly plaques in intertriginous regions such as the axillary, inframammary, and groin regions. The plaques cause discomfort and are difficult to treat. Treatment ranges from topical to systemic and surgical. Despite the variety of treatment options, Hailey-Hailey disease is notoriously difficult to treat with each patient responding uniquely to treatment. There has been evidence of patients with Hailey-Hailey disease experiencing improvement of symptoms with dupilumab injections. Dupilumab has several off-label uses, including allergic contact dermatitis, hand dermatitis, chronic spontaneous urticaria, and alopecia areata, showing promise for its use in dermatology outside of atopic dermatitis and prurigo nodularis. Due to its minimal side effects, dupilumab can be tried for Hailey-Hailey disease with little risk. We present the case of a 37-year-old female with recalcitrant Hailey-Hailey disease who noticed significant improvement on dupilumab.
References
2. Hailey-Hailey Disease: What treatment should we choose?
Crossref DOI link: https://doi.org/10.1016/j.jaad.2018.05.616
3. F. Alamon‐Reig, L. Serra‐García, X. Bosch‐Amate, C. Riquelme‐Mc Loughlin, J.M. Mascaró, Dupilumab in Hailey‐Hailey disease: a case series, Journal of the European Academy of Dermatology and Venereology, 10.1111/jdv.18350, 36, 10, (e776-e779), (2022).
4. Alzahrani N, Grossman-Kranseler J, Swali R, Fiumara K, Zancanaro P, Tyring S, Rosmarin D. Hailey-Hailey disease treated with dupilumab: a case series. Br J Dermatol.
5. Maloney NJ, Tegtmeyer K, Zhao J, Worswick S. Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis. J Drugs Dermatol. 2019 Oct 1;18(10):S1545961619P1053X. PMID: 31603635.
6. Burge SM. Hailey-Hailey disease: the clinical features, response to treatment and prognosis. Br J Dermatol 1992; 126:275–82.2021 Sep;185(3):680-682. doi: 10.1111/bjd.20475. Epub 2021 Jul 5. PMID: 33971025.
7. Jia F, Zhao Q, Shi P, Liu H, Zhang F. Dupilumab: Advances in the off-label usage of IL4/IL13 antagonist in dermatoses. Dermatol Ther. 2022 Dec;35(12):e15924. doi: 10.1111/dth.15924. Epub 2022 Oct 20. PMID: 36219538.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.